TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NextCure ( (NXTC) ) has provided an update.
On July 14, 2025, NextCure, Inc. implemented a one-for-twelve reverse stock split of its common stock, following stockholder approval at the annual meeting on June 20. This corporate action, approved by the board, affects all outstanding shares and reduces the number of shares available under its stock plans while adjusting the exercise price of stock options. The stock will trade on a split-adjusted basis under the ticker ‘NXTC’ on Nasdaq starting July 14, 2025.
The most recent analyst rating on (NXTC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.
Spark’s Take on NXTC Stock
According to Spark, TipRanks’ AI Analyst, NXTC is a Underperform.
NextCure’s overall stock score reflects significant financial challenges, including a lack of revenue and ongoing cash burn typical of early-stage biotech firms. The technical analysis suggests a bearish trend with potential volatility, while valuation metrics are unfavorable due to negative earnings. Despite a positive corporate event related to clinical trials, the company must urgently address its financial sustainability through partnerships or additional funding to enhance its long-term prospects.
To see Spark’s full report on NXTC stock, click here.
More about NextCure
Average Trading Volume: 235,095
Technical Sentiment Signal: Sell
Current Market Cap: $11.08M
For an in-depth examination of NXTC stock, go to TipRanks’ Overview page.